- Home
- CMBT vs HRMY Comparison
CMBT vs HRMY Comparison
Compare CMBT & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMBT
- HRMY
- Stock Information
- Founded
- CMBT 1989
- HRMY 2017
- Country
- CMBT Belgium
- HRMY United States
- Employees
- CMBT N/A
- HRMY N/A
- Industry
- CMBT
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- CMBT
- HRMY Health Care
- Exchange
- CMBT NYSE
- HRMY Nasdaq
- Market Cap
- CMBT 1.9B
- HRMY 1.6B
- IPO Year
- CMBT N/A
- HRMY 2020
- Fundamental
- Price
- CMBT $8.91
- HRMY $34.05
- Analyst Decision
- CMBT
- HRMY Strong Buy
- Analyst Count
- CMBT 0
- HRMY 8
- Target Price
- CMBT N/A
- HRMY $52.88
- AVG Volume (30 Days)
- CMBT 139.5K
- HRMY 714.8K
- Earning Date
- CMBT 05-16-2025
- HRMY 05-06-2025
- Dividend Yield
- CMBT 64.05%
- HRMY N/A
- EPS Growth
- CMBT 4.48
- HRMY 13.13
- EPS
- CMBT 4.44
- HRMY 2.62
- Revenue
- CMBT $940,246,000.00
- HRMY $744,852,000.00
- Revenue This Year
- CMBT $5.05
- HRMY $20.06
- Revenue Next Year
- CMBT $24.22
- HRMY $18.40
- P/E Ratio
- CMBT $2.07
- HRMY $12.99
- Revenue Growth
- CMBT N/A
- HRMY 20.62
- 52 Week Low
- CMBT $7.65
- HRMY $26.47
- 52 Week High
- CMBT $21.26
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- CMBT 45.76
- HRMY 69.53
- Support Level
- CMBT $9.25
- HRMY $29.82
- Resistance Level
- CMBT $9.92
- HRMY $30.61
- Average True Range (ATR)
- CMBT 0.36
- HRMY 1.12
- MACD
- CMBT 0.01
- HRMY 0.74
- Stochastic Oscillator
- CMBT 27.11
- HRMY 92.78
About CMBT EURONAV
CMB.Tech NV owns and operates a fleet of vessels for international maritime shipping and storage of crude oil and petroleum products. It generate a large parts of their revenue from voyage charters, including vessels in pools that predominantly perform voyage charters. The company organizes itself into three divisons: the Marine division, the H2 Infra division and the H2 Industry division. The Marine Division derives maximum revenue.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.